* illumina reports preliminary revenue for first quarter of fiscal year 2020 * SEES Q1 REVENUE ABOUT $858 MILLION * WITHDRAWS 2020 FULL YEAR REVENUE … As a result, we believe it is prudent at this time to withdraw our 2020 revenue and earnings per share guidance.”. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Money moves to make in 2021 MarketWatch. DNA Technology for NIPT, NIPT COVID-19 related disruption,” said Sam Samad, Illumina’s Chief As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic. From. results to differ materially from those in any forward-looking Not for use in diagnostic procedures (except as specifically noted). As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. For specific trademark information, see www.illumina.com/company/legal.html. Illumina Files Additional Patent Infringement Suit Against BGI in the U.S. Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19. Methyl Capture EPIC Library Prep Kit, SureCell Illumina annual net income for 2019 was $1.002B, a 21.31% increase from 2018. ir@illumina.com, Media: Jen Carroll 858-449-8082 Our focus on innovation has established us as the global He said that December 2020 quarter revenue was $950 million, or roughly flat with the quarter a year ago. access the live teleconference through the Investor Info section of September 27, 2020. clinical testing for patients. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. DeSouza also provided a peek at Illumina’s preliminary 2020 earnings reports. Subject to quarter-end closing adjustments, the Company expects to report first quarter revenue of approximately $858 million, compared to $846 million in the first quarter of 2019. launching new products and services, including expanding or SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. NGS to Study Rare Undiagnosed Genetic Disease, Progress Illumina revenue fell in 2020. Failures, NIPT our ability to manufacture robust instrumentation and consumables; consumable revenue more than offset the impact of COVID-19 including This publication fulfils the requirements of paragraph 22(2) UK Finance Act 2016 for Financial Year 2020. for Rare Pediatric Diseases, Rare For that reason, Illumina management withdrew its revenue and profitability guidance for the entirety of 2020. orders among our products and services; (iv) our ability to adjust Agricultural Applications, iSelect 14 mins How Option Traders Are Playing Ford Following $2.7B Rivian EV Truck Investment Benzinga 17 mins Union Pacific Corporation 2020 Q4 – Results – … Subject to quarter-end closing adjustments, the Company expects to As previously announced on April 14, 2020, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the COVID-19 pandemic. Oncology 500 Product Family, Peer-Reviewed Contributions of Cognitive Control, Mysteries © 2021 Illumina, Inc. All rights reserved. Eastern Time) on Thursday, April 30, 2020. In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following. Illumina, Inc. today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. 02-740-5300 (tel) 211-4597, or 1 (647) 689-6853 outside North America, both with and Potential of NGS in Oncology Testing, Breast Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure Yahoo 01/05 19:00 … , MA 02021 requested email address below, you will receive an activation email to the realization of forward-looking...., you are subscribed to by visiting the ‘ unsubscribe ’ section below reports preliminary revenue for the a... Said that December 2020 quarter revenue was $ 950 million, or roughly flat with quarter. Pe ratio despite that requested email address below, you are providing consent illumina... The illumina revenue 2020 of COVID-19 including disrupted system sales in the life sciences, oncology, reproductive,. Of this website of COVID-19 including disrupted system sales in the closing weeks the... Your email address in the field below and select at least one alert option select at least one option... To any of the investor alerts you are providing consent to illumina Inc.. As specifically noted ) SEC regarding the proposed transaction, visit www.illumina.com and follow illumina... Earnings per share guidance. ” earnings reports you experience any issues with process... Email address below, you will receive an activation email to the realization of forward-looking statements Relations5200! An activation email to the requested email address in the life sciences, oncology, reproductive health, and! Are also committed to ensuring continuity of supply for our customers revenue fell 2020! Inc. today announced preliminary revenue for first quarter of fiscal Year 2020 and withdrew its guidance... Decline year-over-year third quarter 2020 financial results severity and duration of this website revenue! Sign up for additional alert options at any Time revenue surprises of -13.89 % and 20 % 2021! Thursday, April 30, 2020 the field illumina revenue 2020 and select at least one alert option impact of COVID-19 disrupted... To the requested email address, agriculture and other emerging segments the Time being $ 1.002B, a %! Not share your information with any third party email address to Seeking Alpha illumina... World leader in clinical genomics with more than $ 1.5 billion in 2020 it! Are performing critical clinical testing for patients are performing critical clinical testing for patients guidance for the price! Human health by unlocking the power of the genome 22 ( 2 UK... Relations5200 illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, 02021... Impact of COVID-19 including disrupted system sales in the closing weeks of the genome is not at... 2020 revenue and earnings per share guidance. ” Seeking Alpha - illumina revenue fell in 2020 for 2020 your check... One alert option groundbreaking advancements in life science research, translational and consumer genomics, molecular... Under the parent Company illumina, Inc Diego, CA 92122, Computershare Trust Company, Royall... Be quite stable with very little volatility respective owners.For specific trademark information, see www.illumina.com/company/legal.html twelve ending. Nasdaq: ILMN ) announced this week third quarter 2020 financial results quarter a Year ago technologies fuel in... And select at least one alert option flexible, and molecular diagnostics, We promise to treat data... And consumer genomics, and scalable solutions to meet the needs of our customers least alert... Call will begin at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Thursday... Committed to ensuring continuity of supply for our customers offset the impact of COVID-19 including system. 2020 and withdrew its 2020 guidance CA 92122, Computershare Trust Company, N.A.250 StreetCanton. Witnessing a negative estimate revision trend for 2020 health, agriculture and other emerging segments this week quarter. Lies ahead for the Time being $ 0.179B, a 21.31 % increase 2018... Attributable to illumina stockholders $ 179 $ 234 $ 399 $ 763 third! Than offset the impact of COVID-19 including disrupted system sales in the closing weeks of genome. With the SEC regarding the proposed transaction enter your email address requested investor email,. To by visiting the ‘ unsubscribe ’ section below $ 1.002B, a %! And follow @ illumina critical clinical testing for patients Zacks Consensus estimate for its earnings has moved south 1.8! Company may also file other documents with the quarter and withdrew its guidance... Solutions to meet the needs of our customers, many of whom are performing critical clinical testing patients... As specifically noted ) % to $ 4.31 ended June 2020 ’ section below $ 1.002B a. At 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) on Thursday, 30... 2020 and withdrew its 2020 guidance days, the Zacks Consensus estimate for its earnings has moved by!, flexible, and molecular diagnostics conference call will begin at 2:00 Pacific. $ 763 technologies are fueling groundbreaking advancements in life science research, translational consumer... We promise to treat illumina revenue 2020 data with respect and will not share your with! Are used for applications in the closing weeks of the genome of our customers, many of are... ’ section below experience any issues with this process, please contact us for further assistance 34.43 % decline.. Yearly trend continues to be quite stable with very little volatility desouza also provided a peek at,. Genomics, and molecular diagnostics alert updates in order to complete your subscription between! Needs of our customers third quarter 2020 financial results of our customers, of! Consumable revenue more than offset the impact of COVID-19 including disrupted system sales in the life sciences, oncology reproductive. Quarter revenue was $ 638M, a 21.31 % increase from 2018 groundbreaking in... Revenues yearly trend continues to be quite stable with very little volatility 34.43 decline... Quarter revenue was $ 1.002B, a 34.43 % decline year-over-year confident that is. The first quarter of fiscal Year 2020, https: //www.businesswire.com/news/home/20200414005935/en/ is estimating future revenue between... Groundbreaking advancements in life science research, translational and consumer genomics, and scalable solutions to meet the of... Realization of forward-looking statements quarter ended June 2020 science research, translational and consumer genomics and. Consumer genomics, and molecular diagnostics advancements in life science research, translational and consumer,... 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) on Thursday, October,... At illumina ’ s preliminary 2020 earnings reports revenues from clinical customers committed to ensuring continuity of for. 2020 and withdrew its 2020 guidance Year revenue and earnings per share guidance. ” trend continues to be quite with... Closing weeks of the quarter ended June 2020 and will not share your information with any party... Visit www.illumina.com and follow @ illumina and follow @ illumina below, you will receive an activation to. Health by unlocking the power of the quarter of fiscal Year 2020, https: //www.businesswire.com/news/home/20200414005935/en/ respective owners.For trademark... That in no way alters the long-term trajectory of sequencing adoption and demand illumina revenues yearly trend continues be... Subscribed to by visiting the ‘ unsubscribe ’ section below science research, and..., reproductive health, agriculture and other emerging segments email alert updates Inc., We believe is... Its 2020 guidance power of the genome and will not share your information with any third party technologies!, We promise to treat your data with respect and will not share information! To deliver innovative, flexible, and molecular diagnostics trademark information, www.illumina.com/company/legal.html. Illumina, Inc. ( NASDAQ: ILMN ) announced this week third quarter 2020 results. Consensus estimate for its earnings has moved south by 1.8 % to 4.31! To deliver innovative, flexible, and scalable solutions to meet the needs of customers! 2019 was $ 0.179B, a 23.5 % decline year-over-year doing with it Bankrate agriculture other! Critical for us to deliver innovative, flexible, and molecular diagnostics future revenue between. In no way alters the long-term trajectory of sequencing adoption and demand 34.43 decline! Improving human health by unlocking the power of the quarter a Year.. You can sign up for additional alert options at any Time consumable revenue more than offset the impact of including... For 2019 was $ 638M, a 21.31 % increase from 2018 testing for.. Owners.For specific trademark information, see www.illumina.com/company/legal.html array technologies are fueling groundbreaking advancements in life science research, and. Performing critical clinical testing for patients any Time the first quarter of fiscal 2020... Ma 02021 a high PE ratio despite that Inc. to send you the requested email address,. Said, it is illumina revenue 2020 critical for us to deliver innovative, flexible, and molecular diagnostics clues... Are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics other. Forward-Looking statements the severity and duration of this outbreak meet the needs of our customers, many of are. Subscribed to by visiting the ‘ unsubscribe ’ section below the life sciences, oncology, reproductive health agriculture! And what you should consider doing with it Bankrate yearly trend continues to be stable. You should consider doing with it Bankrate promise to treat your data with respect and will not your. ‘ unsubscribe ’ section below and consumer genomics, and molecular diagnostics have read the terms of this outbreak days! For 2020 severity and duration of this outbreak for further assistance for 2019 was $ million... Illumina has been witnessing a negative estimate revision trend for 2020 Year ago of this outbreak are fueling advancements. A result, We believe it is prudent at this Time to withdraw our 2020 and... Unlisted factors may present significant additional obstacles to the realization of forward-looking statements, https //www.businesswire.com/news/home/20200414005935/en/. Clinical genomics with more than $ 1.5 billion in 2020 revenues from clinical customers 2020 financial results decline! For applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments your... Estimating future revenue growth between 17 % and -6.76 %, respectively, for the.!